If you or your loved one has relapsed Chronic Lymphocytic Leukemia (#CLL), an important new clinical trial may be an option.
New cancer treatment guidelines say repeated genetic testing is important to making the right treatment decisions and improving outcomes in patients with CLL. As part of the study, participants will receive genetic testing at no cost. This trial is testing whether adding an investigational medication (ublituximab) to ibrutinib (Imbruvica®), an FDA-approved treatment, improves outcomes for high-risk CLL patients.
If you are interested, the full study details and eligibility criteria are listed here.
New Study for People with Severe to Very Severe COPD
This research study is testing whether a new investigational drug that targets eosinophils (a type of white blood cell) could help patients with COPD (chronic obstructive pulmonary disease) control symptoms and reduce exacerbations (flare-ups) that lead to hospitalizations. The new investigational drug will be compared to oral and inhaled corticosteroids, the current standard of care for COPD.